Benitec announces restructuring of Senior Executive team

Mr Bryan Dulhunty commenced in his new role as CFO on 1 July 2016.  Bryan has 20 years' experience in the life sciences sector, and has previously served as Executive Chairman, Non-Executive Director, Managing Director, CFO and Company Secretary of a number of listed and non-listed biotech companies. Bryan holds a Bachelor of Economics from the University of Sydney and is a Chartered Accountant.

"Both Dr Holloway and Mr Dulhunty have strong domestic and international sector experience and dynamic leadership qualities.  These critical new appointments signal an important new era for the company and strengthens our core capabilities. We are now well equipped to meet the challenges ahead of us and position the company for growth.  We are excited to have them on board," said Mr Francis.

The strengthened executive team will draw on its combined decades of leadership and expertise in the global biotechnology and biopharmaceutical sector to lead Benitec forward through the research and development of innovative gene therapy solutions, as well as business development efforts.  The company remains committed to its articulated strategy to develop and enhance its ddRNAi technology platform, establish co-development and collaboration arrangements for non-pipeline projects, and to outlicense ddRNAi to companies who are developing therapeutic programs independently.

Mr Carl Stubbings, the previous Chief Business Officer, left the company, effective 31 July, to pursue other opportunities.  The company wishes him well in his new endeavours.

For further information regarding Benitec and its activities, please contact the persons below, or visit the Benitec website at www.benitec.com

About Benitec Biopharma Limited:    
Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) is a biotechnology company developing innovative therapeutics based on its patented gene-silencing technology called ddRNAi or 'expressed RNAi'. Based in Sydney, Australia with laboratories in Hayward, California (USA), and collaborators and licensees around the world, the company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including hepatitis B, wet age-related macular degeneration and OPMD. Benitec has also licensed ddRNAi to other biopharmaceutical companies for applications including HIV/AIDS, Huntington's Disease, chronic neuropathic pain and retinitis pigmentosa.

Safe Harbor Statement:   
This press release contains "forward-looking statements" within the meaning of section 27A of the US Securities Act of 1933 and section 21E of the US Securities Exchange Act of 1934. Any forward-looking statements that may be in the press release are subject to risks and uncertainties relating to the difficulties in Benitec's plans to develop and commercialize its product candidates, the timing of the initiation and completion of preclinical and clinical trials, the timing of patient enrolment and dosing in clinical trials, the timing of expected regulatory filings, the clinical utility and potential attributes and benefits of ddRNAi and Benitec's product candidates, potential future out-licenses and collaborations, the intellectual property position and the ability to procure additional sources of financing. Accordingly, you should not rely on those forward-looking statements as a prediction of actual future results.

SUMMARY OF KEY TERMS OF THE EXECUTIVE EMPLOYMENT AGREEMENT     
between Benitec Biopharma Limited and Mr Greg West

Position, appointment date and term

Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) has today appointed Mr Greg West as Chief Executive Officer. The term of his employment will continue until terminated in accordance with the Agreement.

Remuneration

(a)    Base salary: A$400,000 per annum, plus statutory superannuation contributions of $19,616.

(b)   Performance bonus: Each year Mr West may receive a performance bonus valued at up to 50% of his Base Salary (given at the discretion of the Board, and measured against the key performance indicators in place for the relevant year).

(c)    Subject to any necessary approvals, Mr West will be entitled to participate in the Benitec Directors' and Officers' Option Plan 2015 in accordance with the rules of the scheme, corporate laws and relevant listing/stock exchange rules.     

Under the Benitec Directors' and Officers' Option Plan 2015, Mr West will be granted options over 2.2 million shares which will vest in tranches over 3 years. The exercise price is calculated by adding a 50% premium to the 30 day Volume Weighted Average Price (VWAP) to the close of business on 10 August 2016. The options will expire five years from the date of granting.

(d)   The Company will review Mr West's performance periodically and may, following a review, elect at its discretion to increase his remuneration or vary his benefits (if any).

Termination

Either Benitec or Mr West may terminate the employment agreement by providing 6 months' written notice.

Benitec may elect for the termination to take effect earlier by making a payment in lieu of notice or may direct Mr West to take leave in that period.

Mr West's employment may also be terminated in instances of serious misconduct, if he fails to carry out his duties or is incapacitated for an extended period.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/benitec-announces-restructuring-of-senior-executive-team-300311620.html

SOURCE Benitec Biopharma Limited